Interestingly, biomarkers may help to select SCLC patients with a higher chance of efficacy of lurbinectedin: preclinical studies showed that a low SLFN11 expression is predicting relative resistance to lurbinectedin, with potential induction of synthetic lethality with ATR inhibitors.11 This evidence concerns the gene ATR and small cell lung carcinoma.